In adults hospitalized with COVID-19, adding baricitinib vs. dexamethasone to remdesivir did not differ for MV-free survival
Sign Up to like & getrecommendations! Published in 2022 at "Annals of Internal Medicine"
DOI: 10.7326/j22-0074
Abstract: SOURCE CITATION Wolfe CR, Tomashek KM, Patterson TF, et al. Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial. Lancet Respir Med. 2022;10:888-99. 35617986. read more here.
Keywords: adults hospitalized; baricitinib; hospitalized covid; adding baricitinib ... See more keywords